• DHBV;
  • antiviral therapy;
  • FMAU;
  • FIAC


The 2′-fluorinated arabinosyl-pyrimidine nucleo- sides, 1-(2′-deoxy-2′-fluoro-P-D-arabinofura- nosyl)-5-iodocytosine (FIAC) and 1-(2′-deoxy- 2′-fluoro-p -D-arabinofuranosyl) -5-methyluracil (FMAU), are new antiviral compounds with in vitro inhibitory activity against the DNA polymerase of hepadnaviruses. Those compounds also induced permanent inhibition of viral replication in woodchucks chronically infected by woodchuck hepatitis virus. The effects of these antiviral compounds were assessed in ducks chronically infected by duck hepatitis B virus (DHBV). Following intraperitoneal administration for 5 days, FMAU (2 mgikgiday) and FIAC (10 mgikgiday) induced a transient decrease in DHBV replication, as shown by the decrease in both the serum and liver DHBV DNA level. After stopping therapy, DHBV replication rebounded immediately to the pretreatment level. The supercoiled form of liver viral DNA was found to be less affected by the therapy. By contrast, no obvious antiviral effect was observed with vidarabine monophosphate (ara-AMP) (80 mglkgiday) therapy. No sign of toxicity was observed during the course of the treatment. These preliminary results confirmed in the DHBV model the higher efficacy of FIAC and FMAU as compared to ara- AMP. Pharmacokinetic studies are needed to ex- plain the differences observed in viral replication in these 2 models of HBV infection. © 1992 Wiley-Liss, Inc.